Shares of Altimmune, Inc. (NASDAQ: ALT - Get Free Report) have been given a consensus rating of "Mod

ALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory ba

ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines,

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemviduti

Dimensional Fund Advisors LP raised its holdings in Altimmune, Inc. (NASDAQ: ALT) by 268.7% during t

Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript

Altimmune NASDAQ: ALT said it has initiated patient enrollment in its global Phase III PERFORMA tria

Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.12) per share which beat the analyst consens

Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2

GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-

Global registrational study designed to evaluate pemvidutide on fibrosis improvement, MASH resolutio

Altimmune, Inc. (ALT) Discusses Topline Results of RECLAIM Phase II Trial of Pemvidutide in Alcohol

Altimmune Inc. (NASDAQ:ALT) has reported positive topline outcomes from its RECLAIM Phase 2 trial as

Altimmune reports positive Phase 2 RECLAIM trial data for pemvidutide in AUD and plans to request an

Altimmune NASDAQ: ALT reported positive top-line results from its Phase II RECLAIM trial evaluating

Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-

Altimmune said on Tuesday its ​experimental drug met ‌the main goal of a mid-stage trial to help ​pe

Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heav

Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heav

Altimmune, Inc. is upgraded to Buy following successful fundraising, providing $535m to fund Phase 3

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Ado

Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook art

Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may pr

Leerink Partners analyst Thomas Smith initiates coverage on Altimmune (NASDAQ:ALT) with a Outperf

Altimmune (ALT) reported earnings 30 days ago. What's next for the stock?

The data are being presented today and Friday in poster sessions, including a late-breaking poster p

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy a

Citizens analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and

Abstract presenting 48-week IMPACT Phase 2b efficacy and safety data selected for inclusion in "

Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.18) per share which beat the analyst consens

Altimmune shares fall after a $225 million offering raises dilution concerns while funding key late-

Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks decl

Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks decl

Altimmune intends to use the net proceeds from this proposed offering to fund its upcoming Phase 3 t

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy a

B. Riley Securities analyst William Woods maintains Altimmune (NASDAQ:ALT) with a Buy and lowers

Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.27) per share. This is a 18.18 percent incre

Altimmune shares are tumbling on Wednesday following the company's announcement of a $75 million